INTRODUCTION

Colorectal stenting is well known to be effective and safe in relieving obstructions, either palliatively or as a bridge to surgery in patients with primary colorectal cancer (1-6). The overall success rate is very high, ranging from 80% to 100% (7-12). Even though there is a high success rate for the stent placement, complications are still encountered. In bare stent placement, recurrent obstruction rates of 3-46% due to tumor ingrowth have been reported (7, 12, 13). Reported recurrent obstruction rates due to tumor ingrowth have been reduced to 0-7% with the use of covered expandable metal stents (14, 15). Although covered stents have been plagued by stent migration problems. While the migration rates associated with bare stent placement have ranged from 3% to 12% (11, 13, 17), the overall migration rates of covered stents have been reported to be as high as 30% to 50% (14, 15, 18).

Objective: To evaluate the safety and effectiveness of a 20-mm diameter dual-design expandable colorectal stent for malignant colorectal obstruction.

Materials and Methods: The study series included 34 patients with malignant colorectal obstruction who underwent implantation of a 20-mm dual-design expandable colorectal stent in our department between March 2009 and June 2010. The 20-mm dual-design expandable colorectal stent was placed by using a 3.8-mm delivery system that had 28-mm diameter proximal and distal ends. Among the 34 patients, stent placement for palliation was performed in 20 patients, while stent placement for bridge to surgery was performed in 14 patients.

Results: A 97% (33 of 34) success rate was achieved for the stent placement. The perforation rate in the bridge to surgery group was 7% (1 of 14), compared to 0% (0 of 19) in palliative group. Migration occurred in one of 33 patients (3%) at 30 days after stent placement.

Conclusion: The placement of a 20-mm diameter dual-design stent appears to be clinically safe and effective for the management of colorectal obstruction, with low perforation and migration rates.

Index terms: Colorectal cancer; Stent; Dual-design; Expandable
Dual-Design Expandable 20-mm Diameter Stent and Malignant Colorectal Obstruction

To overcome migration of the stent and tumor ingrowth, a dual-design expandable colorectal stent has been devised (1). Even though the dual design stent has a low tumor ingrowth rate (3%) and migration rate (3%), the perforation rate is still reported to be 11%, mainly due to upper flared ends of the stent (1). In order to decrease the perforation rate of dual-design stents, Kim et al. (19) designed a study to test the hypothesis that a dual-design colorectal stent with bent ends had lower risk of causing colonic perforations than a dual-design stent with flared ends. However, the rates of colonic perforation did not differ significantly between stent types, nor did the rate of stent-related mortality. In addition, the two stent types had similar technical and clinical success as well as stent migration rates (19).

We hypothesized that a dual stent with a smaller diameter could decrease the rate of perforation due to the low expansion force and better conformability; therefore, placing a smaller diameter stent may be a safe and effective strategy in treating a colorectal obstruction. The aim of this prospective study was to report the clinical results of a 20-mm diameter stent placement in 34 patients with a malignant colorectal obstruction.

MATERIALS AND METHODS

Patients

Informed consent for placement of 20-mm dual-design expandable colorectal stents was obtained for each patient, and our Institutional Review Board approved this prospective study.

Demographic details of all 34 patients are summarized in Table 1. This prospective non-randomized study involved 34 patients with a malignant colorectal obstruction and who were implanted with a 20-mm dual-design expandable colorectal stent in our department between March 2009 and June 2010. The 34 patients consisted of 19 male and 15 female patients ranging in age from 37 to 86 (mean, 59.7) years. Among the 34 patients, stent placement for palliation was performed in 20 patients, while stent placement for bridge to surgery was performed in 14 patients. The indication of palliative stent placement in patients was to relieve bowel obstruction. Inclusion criteria for stent placement were as follows: 1) documented malignancy and 2) bowel obstruction as defined by symptoms resulting in defecation difficulty. Exclusion criteria included asymptomatic patients with malignant colorectal obstruction and who showed clinical evidence of perforation or colorectal obstruction combined with small bowel obstructions. Data collected included demographic information, causes of malignancy, sites and length of obstruction, indications for stent placement, symptom improvement after stent placement, procedure or stent-related complications, management of complications, and expansion of stents.

The underlying causes of obstruction were colorectal carcinoma in 32 patients, ovarian carcinoma in one patient, and metastatic carcinoma of the stomach in one patient. The sites of obstruction included the rectum in five patients, rectosigmoid in three patients, sigmoid in 20 patients, descending colon in three patients, transverse colon in one patient, and ascending colon in two patients. The lengths of stricture ranged from 3 cm to 10 cm (mean, 5.0 cm).

Stents and Stent Introducer Sets

The 20-mm dual stent (S&G Biotech, Seongnam, Korea) consisted of an outer stent and an inner bare nitinol stent (Fig. 1). The outer stent consisted of three parts: a proximal bare nitinol stent (diameter, 28 mm; length, 25 mm), a nylon mesh (diameter, 20 mm), and a distal bare nitinol stent (diameter, 28 mm; length, 25 mm). The inner bare nitinol stent was 20 mm in diameter. The total length of the inner stent was the same as that of the outer stent. The expansion force of the stent was 2.42-N (Newton) in the middle and 1.92-N at both ends. For the previously used 24-mm dual stent, the expansion force was 2.96-N in the middle and 3.60-N at both ends. The expansion force was measured by LR5K PLUS testing machine (AMETEK LLOYD, England). The new inner bare stent could easily be bent without a decrease in the luminal diameter (Fig. 1). The conformability of the inner stent is attributed to the thinner wire used. Previously, the 24-mm inner stent was made of a 0.254-mm wire, but now the new 20-mm inner stent is made of 0.203-mm wire. The delivery system is also smaller for the new stent compared with the 24-mm inner stent, which now is only 3.8 mm, while it was previously 4.5 mm. With the smaller delivery system and more conformable stent, the new stent could be delivered even in the most adverse situations.

The S&G Biotech stent introducer system consisted of a Teflon sheath, 3.8 mm in outer diameter and 80-150 cm in length, a pusher coil catheter, and a guiding olive tip. The outer and inner stents were loaded in their own separate delivery systems.
The details of dual stent placement have been described previously (1). Briefly, with the patient in the left lateral decubitus position, a 0.035-inch guidewire (Radiofocus M, Terumo, Tokyo, Japan) was inserted under fluoroscopic guidance through the anus, across the obstruction, and into the proximal region of the obstruction. After the guidewire was exchanged for a superstiff, 260-cm-long Amplatz guidewire (Medi-tech, Boston Scientific, Boston, MA), the stent delivery system containing the outer component of the stent was passed over the superstiff guidewire, through the obstruction, until the proximal stent had passed through the obstruction. The pusher catheter was held in place, while the sheath was slowly withdrawn, and deployed across the stent stricture. The stent delivery system was removed with the superstiff guidewire left in place. A stent delivery system containing the inner bare component of the stent was then advanced over the superstiff guidewire to

---

### Table 1. Demographic Details of All Patients

| Patient | Sex | Age | Site of Obstruction | Diagnosis | Indication | Complication | Immediate Remedy |
|---------|-----|-----|---------------------|-----------|------------|--------------|------------------|
| 1       | F   | 52  | Rectum             | Ovarian cancer | Palliation | None         |                  |
| 2       | M   | 81  | Ascending colon    | Colorectal cancer | Palliation | None         |                  |
| 3       | M   | 49  | Descending colon   | Colorectal cancer | Palliation | None         |                  |
| 4       | M   | 54  | Sigmoid colon      | Colorectal cancer | Palliation | Incomplete expansion | Balloon dilatation |
| 5       | F   | 37  | Sigmoid colon      | Colorectal cancer | Palliation | None         |                  |
| 6       | M   | 51  | Sigmoid colon      | Colorectal cancer | Palliation | None         |                  |
| 7       | M   | 63  | Sigmoid colon      | Colorectal cancer | Palliation | None         |                  |
| 8       | F   | 47  | Sigmoid colon      | Colorectal cancer | Palliation | Incomplete expansion | Balloon dilatation |
| 9       | M   | 51  | Sigmoid colon      | Colorectal cancer | Palliation | Incomplete expansion | Balloon dilatation |
| 10      | M   | 70  | Sigmoid colon      | Colorectal cancer | Palliation | Incomplete expansion | Balloon dilatation |
| 11      | F   | 60  | Sigmoid colon      | Colorectal cancer | Palliation | None         |                  |
| 12      | M   | 65  | Rectum             | Colorectal cancer | Palliation | None         |                  |
| 13      | M   | 37  | Rectum             | Colorectal cancer | Palliation | Incomplete expansion | Balloon dilatation |
| 14      | M   | 61  | Transverse colon   | Colorectal cancer | Palliation | Incomplete expansion | Balloon dilatation |
| 15      | M   | 68  | Recto-sigmoid      | Colorectal cancer | Palliation | None         |                  |
| 16      | M   | 67  | Descending colon   | Colorectal cancer | Palliation | None         |                  |
| 17      | F   | 68  | Recto-sigmoid      | Colorectal cancer | Palliation | None         |                  |
| 18      | M   | 73  | Sigmoid colon      | Colorectal cancer | Palliation | None         |                  |
| 19      | M   | 64  | Rectum             | Colorectal cancer | Palliation | None         |                  |
| 20      | F   | 55  | Sigmoid colon      | Colorectal cancer | Palliation | Bridge to surgery | None |
| 21      | F   | 55  | Sigmoid colon      | Colorectal cancer | Palliation | Bridge to surgery | None |
| 22      | F   | 38  | Sigmoid colon      | Colorectal cancer | Palliation | None         |                  |
| 23      | M   | 69  | Sigmoid colon      | Colorectal cancer | Palliation | None         |                  |
| 24      | F   | 46  | Recto-sigmoid      | Colorectal cancer | Palliation | Bridge to surgery | None |
| 25      | F   | 62  | Sigmoid colon      | Colorectal cancer | Palliation | Bridge to surgery | None |
| 26      | F   | 49  | Sigmoid colon      | Colorectal cancer | Palliation | Bridge to surgery | None |
| 27      | F   | 86  | Ascending colon    | Colorectal cancer | Palliation | None         |                  |
| 28      | F   | 68  | Sigmoid colon      | Colorectal cancer | Palliation | Bridge to surgery | None |
| 29      | M   | 61  | Descending colon   | Colorectal cancer | Palliation | Bridge to surgery | None |
| 30      | F   | 58  | Sigmoid colon      | Colorectal cancer | Palliation | Bridge to surgery | None |
| 31      | M   | 67  | Rectum             | Stomach cancer   | Palliation | None         |                  |
| 32      | M   | 54  | Sigmoid colon      | Colorectal cancer | Palliation | None         |                  |
| 33      | M   | 65  | Sigmoid colon      | Colorectal cancer | Palliation | None         |                  |
| 34      | F   | 78  | Sigmoid colon      | Colorectal cancer | Palliation | None         |                  |

**Note.** — F = female, M = male
place the inner bare component coaxially into the outer stent.

**Follow Up**
Patients underwent a plain abdominal radiographic examination and a barium study 1 to 3 days after stent placement to assess the expansion and patency of the stent as well as possible complications. Patients for palliation also underwent a barium study one month after stent placement to verify delayed complications, such as stent migration or obstruction. Further follow-up in each patient was based on monthly plain radiography and clinical examinations in the outpatient clinic. A follow-up barium study or endoscopy was performed only in patients with recurrent symptoms. When the performance of clinical examinations was not practical, the patients or their families were contacted by telephone every month until their death. Information was obtained concerning defecation difficulty.

**Interpretation of the Results**
Clinical success was defined as relief of bowel obstruction. Tumor overgrowth was defined as symptomatic narrowing of the stent lumen above or below the covered portion of the stents as a result of tumor growth. Tumor ingrowth was defined as symptomatic narrowing of the stent lumen within the covered portion of the dual stent. Complications including bleeding, pain, tumor overgrowth or ingrowth, perforation, migration, and symptom recurrence were evaluated.

**RESULTS**
The collective technical and clinical success rate of stent placement was 97% (33 of 34). The only failure case was a 49-year-old lady suffering from a sigmoid colon obstruction due to underlying colorectal carcinoma. The colonic carcinoma caused by complete obstruction of the sigmoid colon, with failure to cross the obstruction with the guide wire. She proceeded to operation right after stent placement failure.

A total of 33 stents were placed at the time of the initial stent placement in the 33 patients with successful stent placement (Fig. 2): all patients required only one stent to traverse the site of the obstruction. In six of 33 patients (18%), dilatation of the dual stent using a 14-mm balloon catheter was performed after insertion of the inner bare stent because the diameter of the both placed stent was less than a third of the preset expanded diameter (20 mm).

In all the successful stent placement patients, there was no symptom recurrence until the date of this article was revised (July 2011). The follow-up period ranged from 12 days to 760 days (mean, 335.7 days; median, 297.5 days; standard deviation, 259.1 days). Perforation occurred in one patient two days after stent placement. The perforation rate for the bridge to surgery group was 7% (1 of 14), compared to 0% (0 of 19) for the palliative group. The patient with a perforation suffered from obstructive sigmoid carcinoma and a stent was placed as a bridge to surgery. An emergency colectomy was performed for this patient. The perforation site was at the proximal end of the stent. After nine months of follow up, the patient still performed well without any complication or sign of recurrence.

Migration occurred in one of 33 patients (3%) at 30 days after stent placement. The patient with stent migration was a 37-year-old female suffering from obstructive sigmoid carcinoma. The stent was placed for palliation and subsequently underwent chemotherapy and radiotherapy. The stent was expelled spontaneously one month after chemoradiation.

We did not encounter any tumor ingrowth or overgrowth in this study.

**DISCUSSION**
Recently, colorectal metallic stenting has been performed in lieu of a colostomy for patients that are good candidates for curative surgery to allow time for preoperative bowel
preparation (13, 20-22). Placement of an expandable metallic stent has also been used as a logical method for palliation in patients unsuitable for curative surgery, not only because it avoids a palliative colostomy but also because it reduces hospital stays (17, 23, 24). In previous studies (7-12), there was high success rate in treating colorectal obstructions using metallic stents. However, problems such as migration and perforation were still experienced.

In our study, our success rate in placing the stent was 97%. Among all the successful stent placements, one case of perforation and one case migration were experienced. The perforation rate in the bridge to surgery group was 7% (1 of 14), compared to 0% (0 of 19) for the palliative group. The migration rate was 3% (1 of 33).

The perforation rate was reported to be around 4% of patients who are implanted with colorectal self-expandable metallic stents (8-11), though higher perforation rates (16-83%) have also been reported (25-27). For dual-design expandable metallic stents, the perforation rate was reported to be 22% in the bridge to surgery group, and 5% in the palliative group (1). Kim et al. (19) tried to use a dual-design colorectal stent with bent ends but there was no significant difference noted.

Fig. 2. Illustration of patient with sigmoid colon cancer (patient 11).
A. Water-soluble contrast study with sizing coil catheter during stent placement showing incomplete colonic obstruction. B. Plain radiograph obtained during placement of dual stent showing loaded distal stent. C. Plain radiograph obtained immediately after outer stent placement with loaded inner stent. D. Plain radiograph obtained immediately after stent placement of dual stent showing good flow of contrast medium through stent.
Dual-Design Expandable 20-mm Diameter Stent and Malignant Colorectal Obstruction

Given that a small-diameter stent has a lesser expansion force (28), the risk of perforation may theoretically be reduced. Our study was designed to test the hypothesis that a dual-design colorectal stent with smaller a diameter had a lower risk of causing colonic perforation. As expected, our results indicated that the perforation rate of the new stent measuring 20 mm in the middle and 28 mm at both ends was lower when compared with the larger diameter dual-design stent (24 mm in the middle and 32 mm at both ends). For this new 20-mm dual-design stent, the perforation rate for the bridge to surgery group was only 7%, which was much lower than the 22% previously reported using the larger diameter dual-design stent (1). Even more, the perforation rate for the palliative group attained 0% (0 of 19). The lower perforation rate decreased patient mortality and morbidity.

Migration is another problem for colorectal stenting. The reported migration rates range from 3-12% for the bare metallic stent (11, 13, 17) and 30-50% for the covered stent (14, 16). After employing the newly invented dual-design expandable metallic stent, a significant drop in migration rate was observed. The recent reported migration rate for the 24-mm diameter stent was 3% (1). In our study, even though we used a 20-mm diameter stent, which was expected to have less expansion force (28), we encountered only one case of migration among the 33 stent placements (3%). For this migration case, it was a case of 37-year-old suffering from obstructive sigmoid carcinoma. The stent was put in for palliative purposes. After placement of the stent, the patient underwent through chemotherapy and radiotherapy. We believed that the stent migration was due to the shrinkage of tumor caused by the chemoradiation.

Our study has several limitations. First, the study was not performed in a randomized manner. Second, the study included a small number of patients. Third, the follow-up duration for some of the patients was relatively short due to the death of terminal cases. In conclusion, 20-mm diameter stent placement seems to be clinically safe and effective in patients with a colorectal obstruction, with low perforation and migration rates.

REFERENCES

1. Song HY, Kim JH, Shin JH, Kim HC, Yu CS, Kim JC, et al. A dual-design expandable colorectal stent for malignant colorectal obstruction: results of a multicenter study. Endoscopy 2007;39:448-454
2. Repici A, De Caro G, Luigiano C, Fabbri C, Pagano N, Preatoni P, et al. WallFlex colonic stent placement for management of malignant colonic obstruction: a prospective study at two centers. Gastrointest Endosc 2008;67:77-84
3. Shin SJ, Kim TI, Kim BC, Lee YC, Song SY, Kim WH. Clinical application of self-expandable metallic stent for treatment of colorectal obstruction caused by extrinsic invasive tumors. Dis Colon Rectum 2008;51:578-583
4. Repici A, Fregonese D, Costamagna G, Dumas R, Kahler G, Meisner S, et al. Ultraflex precision colorectal stent placement for palliation of malignant colorectal obstruction: a prospective multicenter study. Gastrointest Endosc 2007;66:920-927
5. Fregonese D, Naspetti R, Ferrer S, Gallego J, Costamagna G, Dumas R, et al. Ultraflex precision colon stent placement as a bridge to surgery in patients with malignant colon obstruction. Gastrointest Endosc 2008;67:68-73
6. Fischer A, Schrag HJ, Goos M, Obermaier R, Hopt UT, Baier PK. Transanal endoscopic tube decompression of acute colonic obstruction: experience with 51 cases. Surg Endosc 2008;22:683-688
7. Baron TH. Colonic stenting: technique, technology, and outcomes for malignant and benign disease. Gastrointest Endosc Clin N Am 2005;15:757-771
8. Repici A, Pagano N, Hervosa CM, Danese S, Nicita R, Preatonpi, et al. Metal stents for malignant colorectal obstruction. Minim Invasive Ther Allied Technol 2006;15:331-338
9. Breitenstein S, Rickenbacher A, Berdajs D, Puhon M, Clavien PA, Demartines N. Systematic evaluation of surgical strategies for acute malignant left-sided colonic obstruction. Br J Surg 2007;94:1451-1460
10. Dionigi G, Villa F, Rovera F, Boni L, Carrafiello G, Annoni M, et al. Colonic stenting for malignant disease: review of literature. Surg Endosc 2007;16 Suppl 1:S153-155
11. Sebastian S, Johnston S, Geoghegan T, Torreggiani W, Buckley M. Pooled analysis of the efficacy and safety of self-expanding metal stenting in malignant colorectal obstruction. Am J Gastroenterol 2004;99:2051-2057
12. Khot UP, Lang AW, Murali K, Parker MC. Systematic review of the efficacy and safety of colorectal stents. Br J Surg 2002;89:1096-1102
13. Camuvez F, Echenagusia A, Simo G, Turegano F, Vazquez J, Barreiro-Meiro I. Malignant colorectal obstruction treated by means of self-expanding metallic stents: effectiveness before surgery and in palliation. Radiology 2000;216:492-497
14. Choo IW, DoYS, Suh SW, Chun HK, Choo SW, Park HS, et al. Malignant colorectal obstruction: treatment with a flexible covered stent. Radiology 1998;206:415-421
15. Jung GS, Song HY, Kang SG, Huh JD, Park SJ, Koo KY, et al. Malignant gastroduodenal obstructions: treatment by means of a covered expandable metallic stent-initial experience. Radiology 2000;216:758-763
16. Grunshaw ND, Ball CS. Palliative treatment of an enterocutaneous fistula with a covered metallic stent. Cardiovasc Intervent Radiol 2001;24:438-440
17. Law WL, Choi HK, Chu KW. Comparison of stenting with emergency surgery as palliative treatment for obstructing
primary left-sided colorectal cancer. *Br J Surg* 2003;90:1429-1433

18. Kang SG, Jung GS, Cho SG, Kim JG, Oh JH, Song HY, et al. The efficacy of metallic stent placement in the treatment of colorectal obstruction. *Korean J Radiol* 2002;3:79-86

19. Kim JH, Song HY, Li YD, Shin JH, Park JH, Yu CS, et al. Dual-design expandable colorectal stent for malignant colorectal obstruction: comparison of flared ends and bent ends. *AJR Am J Roentgenol* 2009;193:248-254

20. Mainar A, De Gregorio Ariza MA, Tejero E, Tobio R, Alfonso E, Pinto I, et al. Acute colorectal obstruction: treatment with self-expandable metallic stents before scheduled surgery--results of a multicenter study. *Radiology* 1999;210:65-69

21. Liberman H, Adams DR, Blatchford GJ, Ternent CA, Christensen MA, Thorson AG. Clinical use of the self-expanding metallic stent in the management of colorectal cancer. *Am J Surg* 2000;180:407-411; discussion 412

22. Meisner S, Hensler M, Knop FK, West F, Wille-Jorgensen P. Self-expanding metal stents for colonic obstruction: experiences from 104 procedures in a single center. *Dis Colon Rectum* 2004;47:444-450

23. de Gregorio MA, Mainar A, Tejero E, Tobio R, Alfonso E, Pinto I, et al. Acute colorectal obstruction: stent placement for palliative treatment--results of a multicenter study. *Radiology* 1998;209:117-120

24. Xinopoulos D, Dimitroulopoulos D, Theodosopoulos T, Tsamakidis K, Bitsakou G, Plataniotis G, et al. Stenting or stoma creation for patients with inoperable malignant colonic obstructions? Results of a study and cost-effectiveness analysis. *Surg Endosc* 2004;18:421-426

25. Scurtu R, Barrier A, Andre T, Houry S, Huguer M. [Self-expandable metallic stent for palliative treatment of colorectal malignant obstructions: risk of perforation]. *Ann Chir* 2003;128:359-363

26. van Hooft JE, Fockens P, Marinelli AW, Timmer R, van Berkel AM, Bossuyt PM, et al. Early closure of a multicenter randomized clinical trial of endoscopic stenting versus surgery for stage IV left-sided colorectal cancer. *Endoscopy* 2008;40:184-191

27. Small AJ, Baron TH. Comparison of Wallstent and Ultraflex stents for palliation of malignant left-sided colon obstruction: a retrospective, case-matched analysis. *Gastrointest Endosc* 2008;67:478-488

28. Kim JH, Song HY, Hu HT, Kang YK, Jung HY, Yook JH, et al. Palliative treatment of malignant gastric outlet obstructions with a large-diameter metallic stent: prospective preliminary study. *J Vasc Interv Radiol* 2010;21:1125-1128